NCT03188536 · OUTCOME

HRQOL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Subscale Score

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) · Source last updated 2020-10-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: score on scale
Interval / dispersion: Standard Deviation
Time frame: Day 1

What was measured

The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment) with a recall period of previous week. Scores from each subscale were transformed from 0 to 100. For the functional scales, high scores represent improvement. For the symptom scales, higher scores represent worsening.

Analysis population: All participants eligible for analyses were included. Overall number of participants analyzed are the participants with data available for analyses.

Groups in this outcome

Multiple Myeloma (MM) Participants

Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	273

Reported measurements

Future perspective

Values in score on scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	58.4	27.7	Not reported	Not reported	Not reported

Body image

Values in score on scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	72.9	34.4	Not reported	Not reported	Not reported

Symptoms of the disease

Values in score on scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	30.7	23.2	Not reported	Not reported	Not reported

Adverse effects of the treatment

Values in score on scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	25.4	17.2	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
27.7
value
58.4
title
Future perspective
categories
measurements
group Id
OG000
spread
34.4
value
72.9
title
Body image
categories
measurements
group Id
OG000
spread
23.2
value
30.7
title
Symptoms of the disease
categories
measurements
group Id
OG000
spread
17.2
value
25.4
title
Adverse effects of the treatment

denoms

counts
group Id
OG000
value
273
units
Participants

description

dispersion Type

Standard Deviation

groups

description
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
id
OG000
title
Multiple Myeloma (MM) Participants

param Type

MEAN

population Description

All participants eligible for analyses were included. Overall number of participants analyzed are the participants with data available for analyses.

reporting Status

POSTED

time Frame

Day 1

title

HRQOL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Subscale Score

type

SECONDARY

unit Of Measure

score on scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice